Friday January 24, 2020 0 comments
CENTENNIAL -- Cell>Point announced it is moving forward with two intra-nuclear therapeutics to more effectively target cancer cells with minimal damage to adjacent healthy cells.
The company said the decision is based on its sponsored chelator and therapeutic research conducted at the University of Texas M.D. Anderson Cancer Center on Platinum-Oncardia and 177Lu-Oncardia, and the positive results of its lung cancer imaging trials with 99mTc-Oncardia.
The company said it believes that Oncardia (a proprietary organic formulation of ethylenedicysteine-glucosamine), which functions as an intra-nuclear compound, will provide an effective means to deliver highly targeted, low-dose therapy with minimal impact to collateral healthy cells.
The research focus will involve studies to treat relapsed aggressive diffuse type B-cell lymphoma and lung cancer. Other cancer targets will likely eventuate from these initial studies, the company said.
The research objective is to target cancers with Platinum or 177Lu (depending on the type of cancer) by delivering the therapy to the nucleus of the diseased cell to cause cell apoptosis.
The cell nucleus contains the DNA and thus controls growth and reproduction. Oncardia targets the nucleus, and the stability of Oncardia allows it to be used with a range of therapeutic isotopes and cold metals.
Cell>Point said that -- based on the affinity of hyperactive cancer cells to maintain metabolic activity using glucose or the transition of cells being depleted of glucose -- Oncardia-based therapeutic compounds should be effective in the treatment of a wide range of cancers.
Theranostic personalized medicine involves the combination of therapy and imaging to improve the detection, staging, treatment and assessment of the patient's response to treatment. No two patients are identical and their responses to treatment for the same type of cancer will not necessarily be the same.
Medical management in oncology is evolving from a generalized approach in the treatment of many forms of cancer to a more patient centric approach. Cell>Point said theranostic medicine should play a central role in this transformation.